A team led by Cecilia Sanjuan-Ortiz of King’s College London, together with colleagues spanning Spain and the United Kingdom, conducted a systematic review following a pre-registered protocol and PRISMA reporting standards. Their search swept across five scientific databases to identify longitudinal studies that followed individuals at clinical high risk and reported which baseline characteristics were associated with remission from the high-risk state. After independent screening and data extraction by four reviewers, the team settled on fifty-one studies encompassing 10,073 participants from fifteen countries. The participants were young, averaging 19.1 years at study level with a range from 13.8 to 28.4 years, and just under half were female. Follow-up periods stretched from as short as eight months to as long as six years, giving researchers a meaningful window into how these young people fared over time.

The headline statistic is striking: roughly one-third of individuals at clinical high risk achieve remission from their CHR-P state at follow-up. That figure reframes the entire clinical conversation. For decades, research in this field has fixated on transition to psychosis, treating the onset of a diagnosable disorder as the outcome that matters most. But the new synthesis, published in the journal Schizophrenia, argues that remission deserves equal billing. A young person whose attenuated symptoms fade and who returns to their previous level of functioning has, in a very real sense, dodged the clinical bullet, and understanding what makes that outcome possible could transform early intervention from a blunt instrument into a precision tool.

Methodologically, the review carries considerable weight. The authors assessed risk of bias using a modified Newcastle-Ottawa Scale, and the results were reassuring: the mean score across studies was 7.7, with 92.1 percent of the included studies rated as high quality. Because the studies differed so substantially in their designs, measures and follow-up windows, the team could not pool results statistically; instead they performed a narrative synthesis, weighing how consistently each candidate predictor appeared across independent cohorts. That consistency, rather than any single effect size, became the currency of the review. A factor that showed up again and again in different countries, different clinics and different decades carries more evidentiary weight than one reported once, however dramatically.

What emerged was a clear hierarchy of predictors. The most robustly replicated factor was baseline functioning: ten separate studies found that individuals who were doing better in their daily lives, at school, at work and in relationships, when they first presented were more likely to remit. Close behind came symptom severity. Seven studies replicated the finding that lower levels of attenuated positive symptoms at baseline predicted remission, while three studies pointed to the same relationship for negative symptoms, the flattening of emotion, motivation and speech that often proves more disabling than hallucinations or delusions. Two studies independently identified lower self-disturbance, the unsettling sense that one’s thoughts, body or sense of self are slipping out of one’s own ownership, as a predictor of recovery.

Cognition emerged as another pillar. Four studies replicated the association between higher baseline verbal learning and later remission, and two studies each supported verbal memory, working memory and visual memory as predictors. The pattern makes intuitive sense: cognitive reserves buffer the impact of emerging symptoms and support the problem-solving, planning and social navigation that recovery demands. But the review did not stop at psychology. Three studies found that a preserved mismatch negativity amplitude, an electrophysiological brain response that fires when the brain detects an unexpected deviation in a repetitive sound stream, predicted remission. The mismatch negativity has long been studied as a candidate biomarker in psychosis research, and its appearance here, in the context of recovery rather than deterioration, suggests it may index the integrity of the very neural prediction machinery that psychosis disrupts.

Perhaps the most futuristic finding concerns language. Two studies replicated the association between speech fluency and connectedness and remission, joining a growing literature in which computational analysis of what patients say, how coherent their narratives are, how semantically rich their word choices, how smoothly their sentences flow, provides a window into underlying neurocognitive function. The idea that a short recorded speech sample could help clinicians stratify risk is no longer science fiction; it is an active frontier, and this review gives it a foothold in the CHR-P field specifically. Alongside these replicated findings, the authors flagged emerging but less consistent evidence for peripheral neurochemical, genetic and psychosocial or environmental factors, domains that remain underexplored and underpowered in the existing literature.

The review is candid about its limits. Substantial heterogeneity across the fifty-one studies, in how remission was defined, how predictors were measured and how long participants were followed, prevented any meta-analytic pooling and limits direct comparability of results. The authors also note that potentially protective factors associated with favourable outcomes remain understudied relative to risk factors, a bias that mirrors the field’s historical preoccupation with deterioration. Most studies examined predictors of remission from the high-risk state itself, but the relationships between remission, transition to psychosis and long-term functional recovery are not always straightforward, and the review stops short of claiming that any single marker can be used clinically today.

Still, the practical message is clear and, in its way, radical. Remission in CHR-P is consistently associated with lower symptom severity at baseline, preserved functioning and better cognitive performance, with self-disturbance, linguistic features and electrophysiological markers emerging as promising supplementary signals. No single domain, demographic, clinical, cognitive, neurophysiological or linguistic, tells the whole story. The authors argue that translation into clinical practice will require integrating information across domains rather than relying on single-domain indicators, effectively calling for multivariable prediction models that weigh a young person’s functioning, symptom profile, cognitive test results and possibly their speech patterns together. For clinicians running early intervention services, that means the most informative assessment may be the broadest one. For the young people and families sitting in those assessment rooms, the review offers something rarer than a risk calculator: evidence that for a substantial minority, and possibly with the right support, a much larger share, the story does not end in psychosis at all. It ends in recovery, and science is finally learning how to see it coming.

Subject of Research: Predictors of remission in individuals at clinical high risk for psychosis

Article Title: Predictors of remission in individuals at clinical high-risk for psychosis: a systematic review

Article References: Sanjuan-Ortiz, C., Laherran-Cantera, N., Aymerich, C., Dully, J., Ahmed, L., Salazar de Pablo, G., & Cella, M. (2026). Predictors of remission in individuals at clinical high-risk for psychosis: a systematic review. Schizophrenia. https://doi.org/10.1038/s41537-026-00809-z

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00809-z

Keywords: clinical high risk for psychosis, CHR-P, remission, psychosis, systematic review, attenuated psychotic symptoms, cognition, verbal learning, mismatch negativity, self-disturbance, speech analysis, early intervention

The research team, led by Xu Yang and Li-Min Xin of Beijing Huilongguan Hospital at Capital Medical University, together with senior author Tian-Mei Si of Peking University Sixth Hospital, recruited participants from a Chinese multicenter cohort known as ODMPIM — Objective Diagnostic Markers and Personalized Intervention in MDD Patients. The trial was registered on ClinicalTrials.gov as NCT02023567 in December 2013, and the study drew on nine psychiatric and general hospitals across China, from Peking University Sixth Hospital and Beijing Anding Hospital to sites in Tianjin, Shanxi, Hebei, Dalian and Shanxi Medical University. Ethics committees at every participating institution approved the protocol, and all participants gave written informed consent under the Declaration of Helsinki.

What makes the design unusually clean is the drug-naïve, first-episode restriction. Most studies of cognition in depression examine patients who have already been exposed to antidepressants, sometimes for years, which makes it difficult to separate the effects of the illness itself from the effects of treatment, chronicity or prior episodes. By enrolling only people who had never received psychotropic medication and were experiencing their first depressive episode, the researchers could ask a purer question: what does depression, in its untreated first appearance, actually do to the thinking brain — and does the answer depend on when in life the disorder first emerged?

The cutoff chosen was 30 years of age at onset. Patients whose depression first appeared before 30 were classified as younger-onset; those whose illness began at 30 or later were classified as older-onset. All patients completed the 17-item Hamilton Depression Rating Scale to quantify depressive severity, the Mini-International Neuropsychiatric Interview to confirm diagnosis, and the Childhood Trauma Questionnaire-Short Form to capture early adversity across emotional, physical and sexual abuse and neglect domains. Healthy controls completed the trauma questionnaire and the same cognitive battery, allowing the team to benchmark both patient subgroups against people without the disorder.

The cognitive assessment spanned five domains, each tapped by established neuropsychological instruments. Processing speed was measured with the Digit Symbol Coding Test and the Color Trial Test. Executive function was probed through the Stroop Color-Word Test and Auditory Verbal Fluency. Attention was assessed with the Continuous Performance Test-Identical Pairs, a demanding task requiring sustained vigilance to fleeting stimulus matches. Verbal learning and memory relied on the Hopkins Verbal Learning Test-Revised, while visual learning and memory used the Brief Visual Memory Test-Revised. Statistical analysis proceeded through multivariate analysis of covariance, followed by correlation and multiple linear regression models that asked which clinical variables best predicted cognitive performance.

The headline result is a stark asymmetry. Younger-onset patients showed impairments across all five cognitive domains relative to healthy controls — processing speed, attention, executive function, verbal learning and visual learning were all affected. Older-onset patients, by contrast, displayed a narrower profile, with deficits confined to processing speed, verbal learning and executive function, while their attention and visual memory performance did not differ significantly from the healthy comparison group. When the two patient subgroups were compared directly, the younger-onset group performed worse than the older-onset group specifically in processing speed and in learning on the Hopkins Verbal Learning Test-Revised, pointing to speed of mental processing and the capacity to acquire new verbal material as the domains most sensitive to early illness onset.

Equally revealing were the results that failed to materialize. Both patient subgroups reported significantly higher levels of childhood trauma than healthy controls, yet the rates of current suicidal ideation — assessed with the Mini-International Neuropsychiatric Interview — were similar between the younger- and older-onset groups. And in the regression models, neither total childhood trauma scores nor Hamilton depression severity predicted cognitive performance. This dissociation matters: it suggests that the cognitive differences between onset groups are not simply a byproduct of more severe depression or a heavier load of early adversity, but may reflect something intrinsic to the developmental timing of the disorder itself.

The regression analyses did surface other predictors. Younger age-at-onset and male sex both predicted poorer processing speed and weaker executive function, reinforcing the picture that an early-arriving illness, particularly in men, is associated with the most pronounced slowing and the greatest difficulty in flexible, goal-directed thinking. In a counterintuitive twist, the presence of suicidal ideation was associated with better processing speed. The authors frame the study as exploratory, and this association in particular invites cautious interpretation — but it hints that the cognitive signatures of depression may not map neatly onto clinical risk in straightforward ways, and that faster processing in some patients may coexist with acute psychological distress.

Why might an earlier onset leave a wider cognitive footprint? The authors’ framing points toward neurodevelopment. Cognitive abilities such as processing speed and verbal learning continue to mature through the third decade of life, and an illness that disrupts brain function during or before this window may interfere with abilities that are still consolidating, or may mark a more neurodevelopmentally rooted form of depression. A later onset, arriving after cognitive systems have fully matured, may spare some domains — attention and visual memory in this dataset — while still eroding speed, verbal learning and executive control. Age-at-onset, in other words, may act as a clinically relevant marker of cognitive heterogeneity, a way of subtyping major depressive disorder that carries direct implications for rehabilitation, occupational counseling and the monitoring of functional recovery in newly diagnosed adults.

The study’s limitations temper but do not erase its significance. The cross-sectional design captures a single moment in time and cannot establish whether early-onset patients will remain more impaired over the course of illness or treatment. The 30-year cutoff, while clinically meaningful, is ultimately a convention, and the authors describe their cognitive patterns as exploratory rather than definitive. Still, the scale of the cohort, the rigor of the five-domain battery and, above all, the drug-naïve first-episode design give the findings unusual weight. For a disorder diagnosed in hundreds of millions of people worldwide, the message is concrete: when a young adult walks into a clinic with a first episode of depression, the age at which the illness began may be one of the most informative numbers on the chart — a signal of how widely cognition has been affected, and of which patients deserve the closest attention to the thinking skills that underpin work, study and daily life.

Subject of Research: Age-at-onset differences in neurocognition, childhood trauma and suicidal ideation in drug-naïve first-episode major depressive disorder

Article Title: Neurocognition, childhood trauma and suicidal ideation in drug-naïve first-episode major depressive disorder: a comparison of younger- versus older-onset patients

Article References: Yang, X., Xin, L.-M., Fan, H.-Z., Lin, J.-Y., Yan, F., Yu, X., Su, Y.-A., & Si, T.-M. (2026). Neurocognition, childhood trauma and suicidal ideation in drug-naïve first-episode major depressive disorder: a comparison of younger- versus older-onset patients. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08695-6

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08695-6

Keywords: major depressive disorder, age-at-onset, neurocognition, childhood trauma, suicidal ideation, drug-naïve, first-episode, processing speed, executive function, verbal learning, BMC Psychiatry, multicenter cohort